MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today reported financial results for the quarter and nine months ended September 30, 2015, and highlighted recent accomplishments and developments. The Company’s lead program has patients enrolling in two Phase 2 clinical trials of enobosarm: one in women with estrogen receptor positive (ER+) and androgen receptor positive (AR+) breast cancer, and another in women with AR+ triple negative breast cancer (TNBC).
Help employers find you! Check out all the jobs and post your resume.
